XDNA Kelly CRISPR & Gene Editing Technology ETF
XDNA Fund Description
XDNA tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology.
XDNA Factset Analytics Insight
XDNA provides vanilla exposure to a very niche segment of the healthcare sector. The fund is passively managed, tracking an index of firms listed in developed markets that are involved in the research and development of DNA modification technology and its applications. Eligible companies must meet investability requirements and should derive significant revenue or profit from business activities related to (i) CRISPR & gene editing technology, (ii) gene editing development solutions, and (iii) gene editing sequencing solutions. The index may include common stocks, REITs, depositary receipts, and preferred stocks of large-, mid-, and small-cap companies. The resulting portfolio holds a maximum of 60 constituents, weighted by market capitalization. The index reconstitutes and rebalances its portfolio on a quarterly basis.
XDNA Summary Data
XDNA Portfolio Data
XDNA Index Data
XDNA Portfolio Management
XDNA Tax Exposures
XDNA Fund Structure
XDNA Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of XDNA. XDNA is rated a N/A out of 5.
XDNA Sector/Industry Breakdown
XDNA Top 10 Holdings[View All]
XDNA Economic Development
XDNA Performance Statistics
XDNA Benchmark Comparison Summary
XDNA Benchmark Comparison Market Cap Size